Pharmacology of Rituximab

Introduction/Overview

Rituximab represents a cornerstone in the therapeutic application of monoclonal antibody technology, marking a significant advancement in the treatment of B-cell mediated disorders. As a chimeric murine-human monoclonal antibody, it specifically targets the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes. Its introduction into clinical practice revolutionized the management of non-Hodgkin’s lymphoma and has since expanded into autoimmune and other immune-mediated conditions. The drug’s mechanism, which depletes B-cells, provides a targeted approach that modulates specific components of the immune system, offering efficacy with a distinct side effect profile compared to traditional cytotoxic chemotherapy. Understanding its pharmacology is essential for the safe and effective application of this biologic agent across multiple medical specialties, including oncology, hematology, rheumatology, and neurology.

Clinical Relevance and Importance

The clinical importance of rituximab is underscored by its broad spectrum of approved indications and its role as a prototype for subsequent anti-CD20 therapies. It was the first monoclonal antibody approved for the treatment of cancer, establishing a new paradigm in oncologic therapeutics. Its utility extends beyond oncology into autoimmune diseases such as rheumatoid arthritis and granulomatosis with polyangiitis, where it provides an alternative for patients refractory to conventional disease-modifying antirheumatic drugs. Furthermore, its use in conditions like pemphigus vulgaris and myasthenia gravis highlights its impact on modulating humoral immunity. The drug’s pharmacokinetic and pharmacodynamic properties necessitate specific administration protocols and monitoring strategies, making a thorough grasp of its pharmacology critical for clinicians and pharmacists involved in patient care.

Learning Objectives

• Describe the structural classification of rituximab as a chimeric monoclonal antibody and its specific molecular target, the CD20 antigen.
• Explain the primary and secondary mechanisms of action through which rituximab mediates B-cell depletion, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct induction of apoptosis.
• Outline the key pharmacokinetic parameters of rituximab, including its volume of distribution, elimination half-life, and the factors influencing its clearance in various patient populations.
• Identify the approved clinical indications for rituximab, distinguishing between its uses in oncologic, autoimmune, and other immune-mediated disorders.
• Recognize the spectrum of adverse effects associated with rituximab therapy, from common infusion-related reactions to serious infectious and immunologic complications, and summarize essential monitoring requirements.

Classification

Rituximab is classified within multiple overlapping therapeutic and chemical categories, reflecting its unique nature as a biologic agent.

Therapeutic and Pharmacologic Classification

The primary pharmacologic classification of rituximab is as a monoclonal antibody. More specifically, it is an anti-CD20 monoclonal antibody. Within therapeutic categories, its classification depends on the indication. In oncology and hematology, it is considered an antineoplastic agent and an immunotherapeutic agent. In rheumatology and other fields treating autoimmune conditions, it is classified as a disease-modifying antirheumatic drug (DMARD), specifically a biologic DMARD. It also falls under the broader category of immunosuppressive agents due to its B-cell depleting action.

Chemical and Structural Classification

Chemically, rituximab is an immunoglobulin G1 kappa (IgG1κ) chimeric monoclonal antibody. The term “chimeric” denotes its hybrid structure: the variable (Fab) regions, which confer antigen specificity, are derived from murine sources (a mouse anti-human CD20 antibody), while the constant (Fc) region is of human origin. This chimerization, approximately 30% murine and 70% human protein sequences, was engineered to reduce immunogenicity compared to a fully murine antibody while retaining high affinity for the CD20 antigen. The human IgG1 Fc region is crucial for engaging human effector mechanisms such as complement and Fc-gamma receptor-bearing cells. The antibody is produced via recombinant DNA technology in Chinese Hamster Ovary (CHO) cell cultures, resulting in a large glycoprotein with a molecular weight of approximately 145 kilodaltons.

Mechanism of Action

The therapeutic efficacy of rituximab is mediated through its specific binding to the CD20 antigen and the subsequent engagement of immune effector mechanisms that lead to the depletion of CD20-positive B-cells. The CD20 antigen is a non-glycosylated phosphoprotein expressed on the surface of pre-B and mature B-lymphocytes, but not on stem cells, pro-B cells, or plasma cells. This expression pattern makes it an ideal target for modulating the B-cell lineage without completely abrogating the capacity for long-term humoral immunity.

Molecular Target: The CD20 Antigen

CD20 is a transmembrane protein that functions as a calcium channel component, playing a role in B-cell activation, differentiation, and cell cycle progression. It is expressed at high density on the cell surface (approximately 100,000 to 200,000 copies per cell) and does not internalize or shed upon antibody binding. This characteristic is pharmacodynamically advantageous, as it allows the antigen-antibody complex to remain on the cell surface for an extended period, facilitating sustained engagement of effector mechanisms. CD20 is not expressed on hematopoietic stem cells, allowing for eventual B-cell reconstitution from precursor pools after therapy is discontinued.

Primary Mechanisms of B-Cell Depletion

Rituximab induces B-cell death through several concurrent and complementary mechanisms. The relative contribution of each mechanism in vivo may vary depending on the disease context, dosing, and host factors.

Complement-Dependent Cytotoxicity (CDC): Upon binding to CD20, the human IgG1 Fc region of rituximab activates the classical complement pathway. This leads to the sequential deposition of complement components C1q, C4b, C3b, and ultimately the formation of the membrane attack complex (C5b-9). The membrane attack complex integrates into the B-cell membrane, creating pores that cause osmotic lysis and cell death. The efficacy of CDC may be influenced by the level of CD20 expression and the complement regulatory proteins expressed by the target cell.

Antibody-Dependent Cellular Cytotoxicity (ADCC): This mechanism involves the recruitment of effector cells of the innate immune system, primarily natural killer (NK) cells, but also macrophages and neutrophils. These effector cells express Fc-gamma receptors (FcγRIIIa, or CD16) that bind to the Fc portion of cell-bound rituximab. This cross-linking triggers the release of cytotoxic granules (containing perforin and granzymes) from NK cells or phagocytic activity by macrophages, leading to apoptosis of the target B-cell. Polymorphisms in the FcγRIIIa gene can influence the affinity of this interaction and may correlate with clinical response in some malignancies.

Direct Induction of Apoptosis: Cross-linking of CD20 by rituximab can transmit intracellular signals that initiate programmed cell death independent of immune effector cells. This direct signaling may involve activation of acid sphingomyelinase, leading to ceramide generation and the formation of lipid rafts, which serve as platforms for pro-apoptotic signaling. This pathway can lead to caspase activation, mitochondrial depolarization, and ultimately apoptosis. The contribution of this direct effect is more pronounced in vitro and its clinical significance in vivo is an area of ongoing investigation.

Secondary Immunologic Effects

Beyond direct B-cell lysis, rituximab exerts several downstream immunomodulatory effects. The depletion of B-cells, which are antigen-presenting cells and sources of cytokines, can disrupt the activation of T-cells. In autoimmune diseases, the removal of autoreactive B-cell clones reduces the production of pathogenic autoantibodies. However, it is noteworthy that clinical improvement in some autoimmune conditions often precedes a significant decline in autoantibody titers, suggesting additional mechanisms such as modulation of cytokine networks or depletion of antigen-presenting B-cells are involved. The drug does not directly target plasma cells, which are CD20-negative, explaining why pre-existing immunoglobulin levels may decline slowly and why patients may remain susceptible to certain infections.

Pharmacokinetics

The pharmacokinetics of rituximab are complex and distinct from small molecule drugs, characterized by nonlinear, time-dependent clearance influenced by the presence of the target antigen (CD20) and the development of anti-drug antibodies.

Absorption

Rituximab is not administered orally due to its proteinaceous nature, which would lead to enzymatic degradation in the gastrointestinal tract. It is administered exclusively via intravenous infusion. Subcutaneous formulations have been developed for some anti-CD20 antibodies but are not standard for the originator rituximab. Following IV administration, the drug enters the systemic circulation directly. The rate of infusion can impact tolerability, with slower initial infusions used to mitigate infusion-related reactions.

Distribution

The volume of distribution at steady state is relatively small, approximately 3 to 4 liters, which is slightly larger than the plasma volume. This limited distribution reflects the drug’s high molecular weight and hydrophilicity, confining it primarily to the vascular and interstitial fluid compartments. Rituximab distributes into lymphoid tissues and sites of disease, such as tumor masses or inflamed synovium, where it binds to CD20-positive B-cells. The binding to this abundant cellular target significantly influences its distribution and clearance kinetics. Serum concentrations show interpatient variability but generally correlate with baseline tumor burden or number of circulating B-cells; higher burden leads to faster initial clearance due to increased antigen-mediated drug elimination.

Metabolism and Elimination

Rituximab, like other IgG antibodies, is not metabolized by hepatic cytochrome P450 enzymes. Its elimination occurs primarily via proteolytic catabolism throughout the reticuloendothelial system, following either binding to the target CD20 antigen or through non-specific IgG clearance pathways. The clearance is nonlinear and is characterized by two distinct phases. Initially, when the target antigen (CD20-positive B-cells) is abundant, clearance is rapid and concentration-dependent due to saturable binding and elimination. As B-cells are depleted and the target becomes limited, clearance transitions to a slower, linear, non-saturable pathway that resembles the elimination of endogenous IgG.

The mean terminal elimination half-life (t_1/2) after the first dose is approximately 22 days (range: 11 to 105 days). With subsequent doses, as the B-cell pool is reduced, the half-life typically increases, often extending to about 30 days or longer. This time-dependent pharmacokinetics means that systemic exposure (measured by area under the curve, AUC) tends to be higher with later doses in a treatment course. Clearance may be faster in patients with high numbers of circulating B-cells or high tumor burden, and slower in patients with low levels of CD20-positive cells.

Pharmacokinetic Parameters and Dosing Considerations

Standard dosing regimens are based on body surface area for oncologic indications (e.g., 375 mg/m²) and fixed doses for autoimmune diseases (e.g., 1000 mg). The nonlinear PK supports the use of repeated dosing to achieve and maintain B-cell depletion. Trough serum concentrations have been investigated as potential predictors of response in some diseases, such as rheumatoid arthritis, where higher drug levels may correlate with better clinical outcomes. Dosing intervals (e.g., weekly, every 6 months) are designed to maintain sufficient drug levels to sustain B-cell depletion. In patients with high tumor burden, a phenomenon known as “antigen sink” can occur, where a large mass of CD20-positive cells rapidly binds and clears the antibody, potentially reducing efficacy; this is sometimes addressed with more frequent initial dosing.

Therapeutic Uses/Clinical Applications

Rituximab has received regulatory approval for a diverse array of conditions, primarily centered on pathologies driven by CD20-positive B-cells. Its use is supported by extensive clinical trial data and real-world evidence.

Approved Indications

Oncologic and Hematologic Malignancies

• Non-Hodgkin’s Lymphoma (NHL): This represents the original and most extensive use. It is approved for:
  • Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL: As a single agent.
  • Previously untreated follicular, CD20-positive B-cell NHL: In combination with chemotherapy (e.g., CVP: cyclophosphamide, vincristine, prednisone) and as maintenance therapy.
  • Non-progressing, low-grade, CD20-positive B-cell NHL: As a single agent after first-line CVP chemotherapy.
  • Previously untreated diffuse large B-cell, CD20-positive NHL: In combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or other anthracycline-based chemotherapy regimens. The R-CHOP regimen is the global standard of care for this aggressive lymphoma.
• Chronic Lymphocytic Leukemia (CLL): Approved in combination with fludarabine and cyclophosphamide (FC) for the treatment of previously untreated and previously treated patients with CD20-positive CLL.

Autoimmune and Inflammatory Disorders

• Rheumatoid Arthritis (RA): Approved in combination with methotrexate for the treatment of adult patients with moderately to severely active RA who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
• Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): Approved in combination with glucocorticoids for the induction of remission in adult patients with these antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.
• Pemphigus Vulgaris: Approved for the treatment of adult patients with moderate to severe disease.

Common Off-Label Uses

Numerous off-label applications are supported by clinical guidelines and evidence, reflecting its potent B-cell depleting action.

• Immune Thrombocytopenic Purpura (ITP): Used in patients with chronic, refractory ITP, particularly those who have failed corticosteroids and splenectomy.
• Autoimmune Hemolytic Anemia (AIHA): Employed in refractory cases, especially warm antibody AIHA.
• Neurologic Disorders: Used in neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis, particularly in anti-acetylcholine receptor antibody-positive patients who are refractory to other immunotherapies.
• Systemic Lupus Erythematosus (SLE): While not universally effective in all SLE manifestations, it is frequently used for refractory lupus nephritis and hematologic involvement.
• Post-Transplant Lymphoproliferative Disorder (PTLD): Often used as first-line therapy for CD20-positive PTLD occurring after solid organ or hematopoietic stem cell transplantation.
• Other Vasculitides: Such as cryoglobulinemic vasculitis, often associated with hepatitis C virus infection.

Adverse Effects

The adverse effect profile of rituximab is a direct consequence of its pharmacodynamic actions—B-cell depletion and immune activation—and its proteinaceous nature. Adverse reactions can be categorized as infusion-related, infectious, immunologic, and others.

Common Side Effects

The majority of adverse effects are mild to moderate in severity and are associated with the initial infusion.

• Infusion-Related Reactions (IRRs): These are the most frequently reported adverse events, occurring in a substantial proportion of patients during the first infusion. Symptoms typically include fever, chills/rigors, nausea, pruritus, rash, angioedema, hypotension, bronchospasm, and fatigue. The pathogenesis is thought to involve cytokine release (e.g., TNF-α, IL-6) from lymphoid cells undergoing lysis. The incidence and severity of IRRs decrease markedly with subsequent infusions. Premedication with antihistamines (e.g., diphenhydramine), acetaminophen, and corticosteroids is standard practice to mitigate these reactions.
• Infections: An increased risk of bacterial, viral, and fungal infections is observed due to B-cell depletion and hypogammaglobulinemia. Common infections include upper respiratory tract infections, bronchitis, and urinary tract infections. The risk is generally higher in patients receiving concurrent chemotherapy or other immunosuppressants.
• Hematologic Effects: Transient cytopenias are common, including lymphopenia (an expected pharmacologic effect), neutropenia, thrombocytopenia, and anemia. Late-onset neutropenia, occurring weeks to months after treatment, has been described, particularly in patients with lymphoma.

Serious and Rare Adverse Reactions

Black Box Warnings

Rituximab carries several boxed warnings, highlighting its most severe risks:

• Fatal Infusion Reactions: Deaths have occurred within 24 hours of infusion, often associated with hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, or cardiogenic shock. These severe reactions are more frequent with the first infusion.
• Severe Mucocutaneous Reactions: Paraneoplastic pemphigus, Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis have been reported, some with fatal outcome.
• Hepatitis B Virus (HBV) Reactivation: This can result in fulminant hepatitis, hepatic failure, and death. Reactivation can occur in patients with resolved infection (positive for hepatitis B core antibody, negative for surface antigen). Screening for HBV prior to initiation is mandatory, and antiviral prophylaxis is recommended for at-risk patients.
• Progressive Multifocal Leukoencephalopathy (PML): A rare, often fatal, opportunistic infection of the central nervous system caused by the JC virus. PML has been reported in patients treated for hematologic malignancies and autoimmune diseases, usually after multiple courses of therapy. Symptoms include progressive neurologic deficits such as hemiparesis, visual field defects, cognitive impairment, and ataxia.

Other Serious Reactions

• Cardiovascular Events: Arrhythmias, angina, and cardiac failure have been reported, particularly in patients with pre-existing cardiac conditions or those receiving cardiotoxic chemotherapy.
• Bowel Obstruction and Perforation: Reported in patients with NHL, sometimes presenting as an abdominal lymphoma involvement.
• Renal Toxicity: Severe, including fatal, renal toxicity can occur in the setting of tumor lysis syndrome or as a consequence of IRRs.
• Immunogenicity: Human anti-chimeric antibodies (HACA) can develop, potentially leading to reduced efficacy, altered pharmacokinetics, or increased risk of hypersensitivity reactions upon re-administration. The reported incidence varies widely across studies and disease states.

Drug Interactions

Formal pharmacokinetic drug interaction studies with rituximab are limited due to its distinct elimination pathway. However, clinically significant pharmacodynamic and safety interactions are well-recognized.

Major Drug-Drug Interactions

• Other Immunosuppressive Agents: Concurrent use with corticosteroids, cytotoxic chemotherapies (e.g., cyclophosphamide, fludarabine), calcineurin inhibitors (e.g., cyclosporine, tacrolimus), or other biologic immunosuppressants (e.g., TNF inhibitors) results in additive or synergistic immunosuppression. This significantly increases the risk of serious infections, including opportunistic infections. While these combinations are often therapeutically intentional (e.g., R-CHOP, use with methotrexate in RA), vigilant monitoring for infection is required.
• Live Vaccines: Administration of live attenuated vaccines (e.g., measles, mumps, rubella, varicella, yellow fever, oral polio) is contraindicated during and after rituximab therapy due to the risk of disseminated vaccine-derived infection. The impaired humoral response also diminishes the efficacy of inactivated vaccines. Vaccinations should ideally be administered at least 4 weeks prior to starting therapy. Inactivated or non-live vaccines can be given during therapy, but the immune response may be suboptimal.
• Antihypertensive Medications: Caution is advised as rituximab infusion can cause hypotension. The effects of concomitant antihypertensives may be potentiated during the infusion period.

Contraindications

Absolute contraindications to rituximab therapy include:

• A history of severe, life-threatening hypersensitivity reaction to rituximab, any component of the formulation, or to murine proteins.
• Active, severe infections.
• Severe, uncontrolled heart failure (New York Heart Association Class IV).
• Concurrent administration of live vaccines.

Relative contraindications require careful risk-benefit assessment and may include:

• Active hepatitis B infection (unless managed with concurrent antiviral prophylaxis).
• Patients with a history of recurring or chronic infections.
• Severe, pre-existing cardiac or pulmonary conditions.
• Significant immunodeficiency (e.g., HIV with low CD4 count).

Special Considerations

Use in Pregnancy and Lactation

Pregnancy: Rituximab is classified as FDA Pregnancy Category C (pre-2015 system) or, under the newer Pregnancy and Lactation Labeling Rule, data suggest a potential risk. Transplacental transfer of IgG antibodies increases during the second and third trimesters. Published case reports and registry data have shown that rituximab exposure during pregnancy can lead to transient B-cell depletion and lymphocytopenia in the newborn. Although no consistent pattern of congenital malformations has been identified, the potential risks to the fetus cannot be ruled out. Use during pregnancy should be reserved for situations where the potential benefit justifies the potential fetal risk. For women of childbearing potential, effective contraception is recommended during treatment and for up to 12 months after the last dose.

Lactation: Human IgG is excreted in human milk. The effects of rituximab on breastfed infants or on milk production are unknown. Given the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Considerations

The safety and efficacy of rituximab in children under 6 months of age have not been established. It is used in pediatric populations for certain conditions, such as relapsed/refractory NHL, CLL, and severe autoimmune cytopenias, often based on extrapolation from adult data and smaller pediatric studies. Pharmacokinetic studies in children with NHL suggest clearance may be faster than in adults, but dosing is generally based on body surface area similar to adult regimens. Special attention must be paid to vaccination status prior to therapy. The long-term effects of profound B-cell depletion on the developing immune system are not fully characterized.

Geriatric Considerations

Clinical studies of rituximab have included elderly patients, and no overall differences in efficacy were observed compared to younger patients. However, a higher incidence of certain adverse events, notably serious cardiac arrhythmias and infections, has been reported in patients over 60 years of age, particularly when rituximab is administered in combination with cytotoxic chemotherapy. Age-related decline in renal or hepatic function is not expected to significantly alter rituximab pharmacokinetics, as it is not eliminated by these organs. Dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.

Renal and Hepatic Impairment

Renal Impairment: Formal pharmacokinetic studies in patients with renal impairment have not been conducted. As renal excretion is not a major pathway for monoclonal antibody elimination, significant impact on rituximab pharmacokinetics is not anticipated. However, caution is warranted in patients with severe renal impairment due to the potential for increased risk of toxicity from concurrent medications (e.g., methotrexate in RA) and the fluid volume load from infusion.

Hepatic Impairment: The influence of hepatic impairment on rituximab pharmacokinetics has not been studied. Since catabolism occurs via widespread proteolytic pathways, hepatic dysfunction is unlikely to have a major effect on clearance. However, patients with pre-existing liver disease, particularly those with hepatitis B or C, require careful monitoring due to the risk of viral reactivation or exacerbation.

Summary/Key Points

• Rituximab is a chimeric anti-CD20 monoclonal antibody of the IgG1κ subclass that mediates depletion of B-cells through CDC, ADCC, and direct apoptotic signaling.
• Its pharmacokinetics are nonlinear and time-dependent, with clearance being rapid initially (target-mediated) and slower during subsequent dosing, resulting in a prolonged terminal half-life that increases with repeated administration.
• Approved indications span hematologic malignancies (e.g., NHL, CLL) and autoimmune disorders (e.g., RA, ANCA-associated vasculitis, pemphigus vulgaris), with numerous evidence-supported off-label uses in other immune-mediated conditions.
• The most common adverse effects are infusion-related reactions, which are typically manageable with premedication and slower infusion rates. Serious risks include fatal IRRs, severe mucocutaneous reactions, HBV reactivation, and PML, necessitating vigilant screening and monitoring.
• Significant drug interactions are primarily pharmacodynamic, involving additive immunosuppression with other agents and contraindication with live vaccines. Special caution is required in pregnancy, lactation, and the elderly.

Clinical Pearls

• Premedication with an antihistamine, acetaminophen, and a corticosteroid is essential to reduce the incidence and severity of infusion-related reactions, especially for the first infusion.
• Mandatory screening for hepatitis B virus (HBsAg and anti-HBc) must be performed prior to initiation, with appropriate antiviral prophylaxis instituted for at-risk patients to prevent fatal reactivation.
• B-cell depletion (CD19+ or CD20+ cell counts) can be used to monitor pharmacodynamic effect, but clinical response is the primary endpoint. Reconstitution of B-cells often takes 6-12 months after a single course, but hypogammaglobulinemia may persist longer.
• In patients with high tumor burden, consider measures to prevent tumor lysis syndrome, such as hydration, allopurinol, and close monitoring of electrolytes and renal function.
• For autoimmune diseases, clinical response may be delayed by several weeks to months following B-cell depletion, and retreatment is typically based on clinical relapse rather than a fixed schedule.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.